全文获取类型
收费全文 | 3602篇 |
免费 | 229篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 119篇 |
妇产科学 | 131篇 |
基础医学 | 565篇 |
口腔科学 | 104篇 |
临床医学 | 308篇 |
内科学 | 782篇 |
皮肤病学 | 47篇 |
神经病学 | 352篇 |
特种医学 | 54篇 |
外科学 | 384篇 |
综合类 | 13篇 |
现状与发展 | 1篇 |
一般理论 | 3篇 |
预防医学 | 331篇 |
眼科学 | 20篇 |
药学 | 260篇 |
中国医学 | 37篇 |
肿瘤学 | 286篇 |
出版年
2023年 | 36篇 |
2022年 | 67篇 |
2021年 | 177篇 |
2020年 | 75篇 |
2019年 | 135篇 |
2018年 | 130篇 |
2017年 | 93篇 |
2016年 | 115篇 |
2015年 | 127篇 |
2014年 | 152篇 |
2013年 | 175篇 |
2012年 | 301篇 |
2011年 | 307篇 |
2010年 | 153篇 |
2009年 | 134篇 |
2008年 | 222篇 |
2007年 | 207篇 |
2006年 | 216篇 |
2005年 | 195篇 |
2004年 | 171篇 |
2003年 | 149篇 |
2002年 | 120篇 |
2001年 | 47篇 |
2000年 | 37篇 |
1999年 | 26篇 |
1998年 | 18篇 |
1997年 | 14篇 |
1996年 | 11篇 |
1995年 | 12篇 |
1994年 | 8篇 |
1993年 | 10篇 |
1992年 | 17篇 |
1991年 | 23篇 |
1990年 | 19篇 |
1989年 | 8篇 |
1988年 | 12篇 |
1987年 | 10篇 |
1986年 | 12篇 |
1985年 | 12篇 |
1984年 | 5篇 |
1983年 | 13篇 |
1982年 | 5篇 |
1981年 | 11篇 |
1980年 | 5篇 |
1979年 | 7篇 |
1976年 | 5篇 |
1975年 | 5篇 |
1974年 | 5篇 |
1973年 | 6篇 |
1969年 | 4篇 |
排序方式: 共有3849条查询结果,搜索用时 31 毫秒
81.
Kathrin Witmer Farah A. Dahalan Michael J. Delves Sabrina Yahiya Oliver J. Watson Ursula Straschil Darunee Chiwcharoen Boodtee Sornboon Sasithon Pukrittayakamee Richard D. Pearson Virginia M. Howick Mara K. N. Lawniczak Nicholas J. White Arjen M. Dondorp Lucy C. Okell Kesinee Chotivanich Andrea Ruecker Jake Baum 《Antimicrobial agents and chemotherapy》2021,65(1)
82.
83.
Alessandra Battaglia Alexia Buzzonetti Cinzia Baranello Mara Fanelli Marco Fossati Valentina Catzola Giovanni Scambia Andrea Fattorossi 《Immunology》2013,139(1):109-120
Interleukin‐2 (IL‐2) is a mainstay for current immunotherapeutic protocols but its usefulness in patients is reduced by severe toxicities and because IL‐2 facilitates regulatory T (Treg) cell development. IL‐21 is a type I cytokine acting as a potent T‐cell co‐mitogen but less efficient than IL‐2 in sustaining T‐cell proliferation. Using various in vitro models for T‐cell receptor (TCR)‐dependent human T‐cell proliferation, we found that IL‐21 synergized with IL‐2 to make CD4+ and CD8+ T cells attain a level of expansion that was impossible to obtain with IL‐2 alone. Synergy was mostly evident in naive CD4+ cells. IL‐2 and tumour‐released transforming growth factor‐β (TGF‐β) are the main environmental cues that cooperate in Treg cell induction in tumour patients. Interleukin‐21 hampered Treg cell expansion induced by IL‐2/TGF‐β combination in naive CD4+ cells by facilitating non‐Treg over Treg cell proliferation from the early phases of cell activation. Conversely, IL‐21 did not modulate the conversion of naive activated CD4+ cells into Treg cells in the absence of cell division. Treg cell reduction was related to persistent activation of Stat3, a negative regulator of Treg cells associated with down‐modulation of IL‐2/TGF‐β‐induced phosphorylation of Smad2/3, a positive regulator of Treg cells. In contrast to previous studies, IL‐21 was completely ineffective in counteracting the suppressive activity of Treg cells on naive and memory, CD4+ and CD8+ T cells. Present data provide proof‐of‐concept for evaluating a combinatorial approach that would reduce the IL‐2 needed to sustain T‐cell proliferation efficiently, thereby reducing toxicity and controlling a tolerizing mechanism responsible for the contraction of the T‐cell response. 相似文献
84.
Crutel Véronique Lambert Estelle Penelaud Pierre-François Albarrán Severo Cristina Fuentes Joaquin Rosier Antoine Hervás Amaia Marret Stéphane Oliveira Guiomar Parellada Mara Kyaga Simon Gouttefangeas Sylvie Bertrand Marianne Ravel Denis Falissard Bruno 《Journal of autism and developmental disorders》2021,51(8):2973-2973
Journal of Autism and Developmental Disorders - The author of the article would like to add a video abstract as a supplementary material for a published article. The supplementary file is published... 相似文献
85.
Mara Cerqueiro Bybrant Lena Grahnquist Eva Örtqvist Cecilia Andersson Gun Forsander Helena Elding Larsson 《Autoimmunity》2013,46(5):221-227
AbstractObjectives: This study explored the association between tissue transglutaminase autoantibody (tTGA), high-risk human leucocyte antigen (HLA) genotypes and islet autoantibodies in children with newly diagnosed type 1 diabetes (T1D).Patients and methods: Dried blood spots and serum samples were taken at diagnosis from children <18?years of age participating in Better Diabetes Diagnosis (BDD), a Swedish nationwide prospective cohort study of children newly diagnosed with T1D. We analyzed tTGA, high-risk HLA DQ2 and DQ8 (DQX is neither DQ2 nor DQ8) and islet auto-antibodies (GADA, IA-2A, IAA, and three variants of Zinc transporter; ZnT8W, ZnT8R, and ZnT8QA).Results: Out of 2705 children diagnosed with T1D, 85 (3.1%) had positive tTGA and 63 (2.3%) had borderline values. The prevalence of tTGA was higher in children with the HLA genotypes DQ2/2, DQ2/X or DQ2/8 compared to those with DQ8/8 or DQ8/X (p?=?.00001) and those with DQX/X (p?≤?.00001). No significant differences were found in relation to islet autoantibodies or age at diagnosis, but the presence of tTGA was more common in girls than in boys (p?=?.018).Conclusion: tTGA at T1D diagnosis (both positive and borderline values 5.4%) was higher in girls and in children homozygous for DQ2/2, followed by children heterozygous for DQ2. Only children with DQ2 and/or DQ8 had tTGA. HLA typing at the diagnosis of T1D can help to identify those without risk for CD. 相似文献
86.
Farah Breno Quintella do Prado Wagner Luiz Malik Neal Lofrano-Prado Mara Cristina de Melo Paulo Henrique Botero Joao Paulo Cucato Gabriel Grizzo de Almeida Correia Marilia Ritti-Dias Raphael Mendes 《Sport Sciences for Health》2021,17(2):441-447
Sport Sciences for Health - Social isolation due to the coronavirus disease 2019 (COVID-19) pandemic has reduced physical activity levels in both men and women. The identification of barriers to... 相似文献
87.
88.
Miguel ngel Hernndez‐Rodríguez Ermengol Sempere‐Verdú Caterina Vicens‐Caldentey Francisca Gonzlez‐Rubio Flix Miguel‐García Vicente Palop‐Larrea Ramn Orueta‐Snchez
scar Esteban‐Jimnez Mara Sempere‐Manuel María Pilar Arroyo‐Anis Buenaventura Fernndez‐San Jos 《Pharmacoepidemiology and drug safety》2020,29(4):433-443
89.
90.